



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




Montelukast

Item No. 35779

CAS Registry No.: 158966-92-8
Formal Name: 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropaneacetic acid

Synonym: MK-476
MF: C₃₅H₃₆ClNO₃S
FW: 586.2
Purity: ≥98%
UV/Vis.: λ_{max}: 245, 284, 327, 359 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Montelukast is supplied as a solid. A stock solution may be made by dissolving the montelukast in the solvent of choice, which should be purged with an inert gas. Montelukast is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of montelukast in these solvents is approximately 2 mg/ml.

Description

Montelukast is a cysteinyl leukotriene 1 (CysLT₁) receptor antagonist (IC₅₀ = 4.9 nM in HEK293 cell membranes expressing the human receptor).¹ It is selective for CysLT₁ over CysLT₂ receptors (IC₅₀ = >10,000 nM in COS-7 cell membranes expressing the human receptor).² Montelukast inhibits bronchoconstriction induced by leukotriene D₄ (LTD₄; Item No. 20310) in anesthetized guinea pigs (ED₅₀ = 69 nmol/kg, p.o.).³ It inhibits ovalbumin-induced airway hyperresponsiveness and increases in the number of total cells and eosinophils in bronchoalveolar lavage fluid (BALF) in a mouse model of allergic asthma when administered at doses of 3 and 10 mg/kg.⁴ Formulations containing montelukast have been used in the treatment of asthma, allergic rhinitis, and exercise-induced bronchoconstriction.

References

1. Sarau, H.M., Ames, R.S., Chambers, J., *et al.* Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. *Mol. Pharmacol.* **56**(3), 657-663 (1999).
2. Heise, C.E., O'Dowd, B.F., Figueroa, D.J., *et al.* Characterization of the human cysteinyl leukotriene 2 receptor. *J. Biol. Chem.* **275**(39), 30531-30536 (2000).
3. Cabré, F., Carabaza, A., García, A.M., *et al.* Pharmacological profile of MEN91507, a new CysLT₁ receptor antagonist. *Eur. J. Pharmacol.* **451**(3), 317-326 (2002).
4. Eum, S.Y., Maghni, K., Hamid, Q., *et al.* Involvement of the cysteinyl-leukotrienes in allergen-induced airway eosinophilia and hyperresponsiveness in the mouse. *Am. J. Respir. Cell Mol. Biol.* **28**(1), 25-32 (2003).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM